Floatz logo

Carboplatin

Camrelizumab

Tongji UniversitySmall moleculePhase 4 / ApprovedActive
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Camrelizumab cohort.

Asset / SponsorPhaseRating
Thalidomide
Tongji University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Tongji University
Phase 4BB
Inno-206
Guohui Xu
Phase 3B
Rivoceranib
Guohui Xu
Phase 3B
Eloxatin
Guohui Xu
Phase 3B
Docetaxel
Zhenzhen Liu
Phase 2CCC
LENVATINIB
Sun Yat-sen University
N/AD

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →